When Constipation on Wegovy (semaglutide 2.4 mg) Becomes a Reason to Stop

How common constipation is on 2.4 mg

In the three pooled placebo-controlled weight-management trials — 2,116 adults on Wegovy 2.4 mg weekly and 1,261 on placebo, treated for up to 68 weeks — constipation was reported by 24% versus 11%, and any gastrointestinal reaction by 73% versus 47% [1]. Nausea (44% vs 16%) and diarrhea (30% vs 16%) were more common than constipation in the same table [1].

A separate meta-analysis of nine randomized trials in adults with overweight or obesity and no diabetes (11,641 on semaglutide, 10,479 on placebo) also found higher odds of constipation with semaglutide than with placebo (odds ratio 2.43) [2]. A network meta-analysis of 39 studies covering 33,354 people associated semaglutide and liraglutide with increased constipation risk, while cagrilintide and exenatide showed no significant increase [3].

Semaglutide delays gastric emptying, and constipation is a reported adverse reaction with Wegovy [1].

What the Wegovy label records about severity

The prescribing information tracks severity in other ways: how many people stopped treatment, a warning for severe gastrointestinal reactions, and reports received after marketing.

A stopping rate for adverse reactions overall. 6.8% of adults on 2.4 mg and 3.2% on placebo stopped treatment permanently because of adverse reactions; the most common reasons were nausea (1.8% vs 0.2%), vomiting (1.2% vs 0%) and diarrhea (0.7% vs 0.1%) [1]. Those are the reactions the label names as leading causes of discontinuation in the weight-management trials.

A warning for severe gastrointestinal reactions. The label states that Wegovy use has been associated with gastrointestinal adverse reactions, sometimes severe, and that the drug is not recommended in patients with severe gastroparesis [1]. Severe GI reactions were reported by 4.1% of adults on Wegovy injection versus 0.9% on placebo [1].

Postmarketing reports of the worst cases. Ileus, intestinal obstruction and severe constipation including fecal impaction are listed as reports received after marketing, and the label says frequency cannot be estimated from voluntary reports [1].

Other situations where the label says to discontinue Wegovy

Acute pancreatitis. The label says to observe patients for persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting, and that Wegovy is to be discontinued if pancreatitis is suspected, with appropriate management started [1]. Confirmed acute pancreatitis occurred in 4 Wegovy-treated adults (0.2 per 100 patient-years) versus 1 on placebo [1].

Hypersensitivity. Anaphylaxis and angioedema have been reported after marketing; the label says to discontinue Wegovy if a hypersensitivity reaction is suspected [1].

Does a higher dose mean worse constipation?

The dose ladder runs 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, then maintenance from week 17 at 2.4 mg or 1.7 mg. Adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss may go to a maximum of 7.2 mg weekly [1].

Two 72-week trials compared 7.2 mg (1,311 people), 2.4 mg (304) and placebo (303). Constipation was reported by 20% on 7.2 mg, 19% on 2.4 mg and 8% on placebo — a much flatter difference than for nausea (39%, 35% and 13%) or dysesthesia, the altered skin sensation such as burning or pain from touch (22%, 6% and 0%) [1]. Stopping treatment for adverse reactions was 5% on 7.2 mg, 5% on 2.4 mg and 2% on placebo [1]. These percentages are for the 7.2 mg treatment arm, including dose escalation; they are not constipation rates measured only while taking 7.2 mg. The label reports 1,311 people exposed in that arm, 1,149 who received at least one 7.2 mg dose after escalation and 578 who took 7.2 mg for at least a year [1].

If Wegovy is stopped, what happens to weight

Weight regain data come from two trials.

In an off-treatment extension of STEP 1, 327 participants had a mean weight loss at week 68 of 17.3% on semaglutide versus 2.0% on placebo. One year after stopping, the semaglutide group had regained 11.6 percentage points, leaving a net loss of 5.6% from baseline at week 120 versus 0.1% for placebo, and most cardiometabolic improvements had moved back toward baseline [4].

In STEP 4, 803 adults who reached 2.4 mg during a 20-week run-in were randomized to continue semaglutide or switch to placebo for 48 weeks. From week 20 to week 68, weight changed by -7.9% in those who continued and +6.9% in those switched to placebo [5].

Constipation with other drugs in the class

A 2024 review of obesity medications put constipation across the nutrient-stimulated hormone drugs (liraglutide, semaglutide and tirzepatide) at 11% to 24% [6].